The total organic synthesis and enzyme-catalyzed biogenic synthesis of the newly uncovered mediator 4S,5R-RCTR1 have been achieved, allowing complete structural elucidation of this novel cysteinyl-resolvin. In addition, potent stereoselective and nanomolar-range actions of 4S,5R-RCTR1 with human M2-like macrophages include phagocytosis of live E. coli, efferocytosis of apoptotic neutrophils, and erythrophagocytosis of senescent red blood cells. These bioactivities are among the defining functions of pro-resolving mediators and highlight the role of resolvins as agonists of resolution of inflammation and tissue repair.

D'Alessandro et al. identify red blood cell metabolic markers of hemolysis and cardiorenal dysfunction in 587 sickle cell patients from the WALK PHASST study.

Proposed treatment paradigms: Hydroxyurea (HU) should be given to all patients at maximally tolerated doses. In patients aged ≥4 years, with hemoglobin F (HbF) ≥30% and continued Vaso Occlusive Events (VOEs)and hemolytic anemia even with maximally tolerated doses (MTD) of HU we recommend starting voxelotor. In individuals ≥16 years, crizanlizumab might be the first drug added to HU if intravenous access is available.

This phase IIb clinical trial evaluated the efficacy of a bimonthly treatment schedule (Q8W) with 4 subcutaneous doses of denosumab 120 mg among adults with Langerhans cell histiocytosis needing first-line systemic therapy for either multifocal single-system disease or multisystem disease without risk organ involvement. Two months after the last treatment administration, seven patients showed disease regression, one stable disease, one non-active disease, and one disease progression. One year after treatment, progression was evident in two patients, while the remaining exhibited either a regression (three patients) or non-active disease (five patients). No permanent sequalae developed during the study and no adverse events were adjudicated in treatment. In conclusion, four doses of denosumab 120 mg Q8W subcutaneously are an effective treatment option in Langerhans cell histiocytosis patients without risk organ involvement exhibiting a response rate of 80%. Further studies are needed to confirm its role as a disease modifying agent.

Overall survival for chronic lymphocytic leukemia (CLL) patients by race; propensity score matched by age, Charlson-Deyo comorbidity score, insurance, and income and education level of zip code of residence.

A violin plot demonstrating listed chargemaster charges for RBC transfusion at 200 hospitals based on hospital ownership. A violin plot shows the volume of the samples at each point by width and lines correspond to the 25th percentile, median, and 75th percentile.